# VT3989

Source: https://onco.cc/drugs/vt3989/  
OnCo record `vt3989` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VT3989 is an experimental pill from Vivace Therapeutics, in phase 2 trials for mesothelioma.

## Summary

VT3989 is a small molecule, oral from Vivace Therapeutics. Stops TEAD transcription factors in the Hippo pathway from attaching a fatty acid to themselves (autopalmitoylation), which they need to drive cancer cell growth. Its phase 1/2 study (NCT04665206) is recruiting people with solid tumours, mesothelioma and non-small cell lung cancer; a phase 3 study in pleural mesothelioma (NCT07824986) is registered and not yet recruiting. TEAD has no target record in OnCo.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: VT3989
- Modality: Small molecule, oral
- Mechanism: Stops TEAD transcription factors in the Hippo pathway from attaching a fatty acid to themselves (autopalmitoylation), which they need to drive cancer cell growth.

## Sources

- Vivace Therapeutics Series D release, March 2025: https://www.biospace.com/press-releases/vivace-therapeutics-raises-35-million-in-series-d-financing-to-support-clinical-development-of-first-in-class-cancer-drug-targeting-the-hippo-pathway
- ClinicalTrials.gov NCT04665206: https://clinicaltrials.gov/study/NCT04665206
- ClinicalTrials.gov NCT07824986: https://clinicaltrials.gov/study/NCT07824986

## Connected records

- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Pleural mesothelioma](https://onco.cc/cancers/pleural-mesothelioma/)
- companies: [Vivace Therapeutics](https://onco.cc/companies/vivace-therapeutics/)
- trials: [A Phase 3 Trial in Advanced Epithelioid Mesothelioma](https://onco.cc/trials/nct07824986/), [Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors](https://onco.cc/trials/nct04665206/)

---
JSON: https://onco.cc/api/v1/entities/vt3989.json